摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-amino-4-bromo-N-((3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl)-2-naphthamide | 1268515-67-8

中文名称
——
中文别名
——
英文名称
1-amino-4-bromo-N-((3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl)-2-naphthamide
英文别名
1-amino-4-bromo-N-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]-2-naphthamide;1-amino-4-bromo-N-[(3R,4S)-3-hydroxyoxan-4-yl]naphthalene-2-carboxamide
1-amino-4-bromo-N-((3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl)-2-naphthamide化学式
CAS
1268515-67-8
化学式
C16H17BrN2O3
mdl
——
分子量
365.227
InChiKey
UIMUVZILIUNALI-KBPBESRZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    22
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    84.6
  • 氢给体数:
    3
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DE RÉCEPTEUR M1 DE TYPE PYRANYL-ARYL-MÉTHYL-BENZOQUINAZOLINONE
    申请人:MERCK SHARP & DOHME
    公开号:WO2011025851A1
    公开(公告)日:2011-03-03
    The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
    本发明涉及式(I)的吡喃基芳基甲基苯并喹唑啉酮化合物,这些化合物是M1受体阳性变构调节剂,可用于治疗M1受体参与的疾病,如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在治疗由M1受体介导的疾病中的用途。
  • PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
    申请人:Kuduk Scott D.
    公开号:US20120157438A1
    公开(公告)日:2012-06-21
    The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
    本发明涉及式(I)的吡喃基苯基甲基苯并喹唑酮化合物,它们是M1受体正向变构调节剂,可用于治疗M1受体参与的疾病,如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包括该化合物的制药组合物,以及使用该化合物和组合物治疗M1受体介导的疾病。
  • DIHYDROBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
    申请人:Kuduk Scott D.
    公开号:US20130184298A1
    公开(公告)日:2013-07-18
    The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
    本发明涉及式(I)的二氢苯并喹唑酮化合物,它们是M1受体正向变构调节剂,并且在治疗M1受体参与的疾病,如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。本发明还涉及包括该化合物的制药组合物,以及使用该化合物和组合物治疗通过M1受体介导的疾病。
  • N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
    申请人:Kuduk Scott D.
    公开号:US20150065498A1
    公开(公告)日:2015-03-05
    The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
    本发明涉及一般式(I)的N-连接内酰胺化合物,它们是M1受体正向变构调节剂,可用于治疗M1受体参与的疾病,例如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含这些化合物的药物组合物,以及在治疗M1受体介导的疾病中使用这些化合物和组合物的方法。
  • Pyranyl aryl methyl benzoquinolinone M1 receptor positive allosteric modulators
    申请人:Merck Sharp & Dohme Corp.
    公开号:US09260418B2
    公开(公告)日:2016-02-16
    The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
    本发明涉及式(I)的吡喃基芳基甲基苯并喹唑啉酮化合物,它们是M1受体正向变构调节剂,可用于治疗与M1受体有关的疾病,如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包括该化合物的制药组合物,以及在治疗由M1受体介导的疾病中使用该化合物和组合物的方法。
查看更多